Weather Alert

High Tech mRNA Shingles Vaccine In The Works

Medical Person with a light blue latex glove injecting the arm of a person with a vaccine syringe. Photo from Alpha Media Portland OR
Medical Person with a light blue latex glove injecting the arm of a person with a vaccine syringe. Photo from Alpha Media Portland OR

Pfizer and BioNTech are working on an mRNA-based shingles vaccine.

Shingles affects one in three Americans, that’s 33%.

Comparatively, right now, Covid-19 is only impacting 1 in 6 Americans, that’s 16%.

The companies are set to use Pfizer’s antigen technology and BioNTech’s mRNA technology to help further prevent shingles.

Shingles usually occurs in older adults who had a chickenpox infection decades earlier, usually when they were children.

The clinical trials for the mRNA shingles vaccine are expected to start in the second half of 2022.

Although a shingles vaccine already exists, Pfizer and BioNTech will work to create one that has “better tolerability” and is easier to make worldwide.

 

Medical Person with a light blue latex glove injecting the arm of a person with a vaccine syringe.

Photo from Alpha Media Portland OR

 



Connect With Us Listen To Us On